Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Roche Holding AG

    OTC: RHHBY · Real-Time Price · USD
    40.11
    -1.13 (-2.74%)
    At close: Jun 16, 2025, 3:59 PM
    -2.74%
    Bid 40.05
    Market Cap 259.48B
    Revenue (ttm) 89.47B
    Net Income (ttm) 17.76B
    EPS (ttm) 1.57
    PE Ratio (ttm) 25.55
    Forward PE 14.14
    Analyst n/a
    Ask 40.19
    Volume 103,887
    Avg. Volume (20D) 2,423,733
    Open 40.82
    Previous Close 41.24
    Day's Range 40.11 - 40.97
    52-Week Range 33.76 - 44.31
    Beta 0.17

    About RHHBY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol RHHBY
    Website n/a
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    9 months ago
    -5.89%
    Roche shares are trading lower following weight lo... Unlock content with Pro Subscription
    news image

    1 day ago · seekingalpha.com

    Roche: Despite Venclexta Study Failure, PD Program Is Another Growth Avenue

    Genentech and AbbVie noted that Venclexta failed to help treat patients with newly diagnosed higher-risk MDS; However, this drug has already been approved for several other hematological indications. ...

    news image

    22 hours ago · businesswire.com

    Genentech Provides Update on Phase III Verona Study

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase III VERONA study (NCT04401748) ...

    news image

    23 hours ago · zacks.com

    RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

    Roche is set to advance prasinezumab into phase III for early Parkinson's, eyeing potential first-in-class disease-modifying therapy.

    news image

    1 day ago · wsj.com

    Roche Pauses Commercial and Clinical Use of Elevidys After Fatal Liver Failures

    The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

    news image

    1 day ago · businesswire.com

    Genentech to Advance Prasinezumab Into Phase III Development for Early-Stage Parkinson's Disease

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, a...

    news image

    1 week ago · reuters.com

    Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients

    Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death com...

    1 week ago · youtube.com

    I own gold, yen and German bunds, 'won't own U.S. treasuries at all': David Roche

    David Roche from Quantum Strategy criticizes President Trump's intention to influence the Fed on monetary policy.

    news image

    2 weeks ago · wsj.com

    Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says

    The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.

    news image

    2 weeks ago · businesswire.com

    Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezo...

    news image

    2 weeks ago · businesswire.com

    New Data Show Genentech's Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the...

    Add to Watchlist